2003-2005: Organisation and structuring
2003 Creation of the Novacap group, Bain Capital is the group’s majority shareholder
2004 Launch of a new sodium bicarbonate unit
2006-2011: Organic development improvement
2006 Launch of the calcium chloride unit in Pont-de-Claix
2008 Launch of the second sodium bicarbonate unit
2010 Launch of the Isopropanol unit in Roussillon
2011 Ardian acquires 96% of Novacap
2011-2016: Growth acceleration and internationalisation
2011 Start-up of the third sodium bicarbonate unit
2011 Acquisition of Novacyl, worldwilde leader in Aspirin, salicylic acid and its derivated
2011 Launch of a new ferric chloride production unit in Pont-de-Claix (France)
2012 Capacity increase on alpha methyl styrene
2013 Acquisition of a majority stake (51%) in Yangzi Pharmaceutical Chemical in China
2014 Launch of homosalate and sodium silicates.
2014 Acquisition of a 51% majority stake in Puyuan .
2015 Acquisition of Uetikon a German-based APIs and fine chemicals manufacturer.
2015 Novacap enters into a partnership with the innovative biotechnology startup Alganelle, specialised in the development and production of high added-value molecules, derived from microalgae.
2016 EURAZEO becomes the majority shareholder of the group alongside MERIEUX development, ARDIAN and the management team.
Since 2016 : Strengthening the technological and products offering for the pharmaceutical, cosmetics and fine chemistry markets.
2017 Novacap acquires 96.5% of Puyuan
2017 Novacap acquires 77.57% of Yangzi Pharmaceutical Chemical
April 2017 Novacap announced a project of strategic combination with PCAS, specialising in the development and production of complex molecules for life sciences and innovative technologies, through a sale of blocks of shares followed by a tender offer.
April 2017 Launch of a new production unit for manufacturing DIPE (Diisopropyl Ether) on the Roussillon chemical platform.
May 2017 Novacap acquires ID bio, a manufacturer of botanical ingredients and H2B, a manufacturer of ingredients for in-vitro diagnosis.
May 2017 Novacap acquires PCAS, specializes in the development and production of complex molecules for life sciences and innovative technologies (cDMO).
July 2017 Acquisition of a majority stake in Chemoxy International Ltd, a leading contract manufacturer for specialty chemicals and environmentally-friendly solvents.
December 2017 Novacap supports Harmonic Pharma, an innovative company specialized in Polypharmacology through a capital increase.
June 2018 Novacap acquires PCI Synthesis, a leading U.S. pharmaceutical contract development and manufacturing organization (CDMO),